Ignite Creation Date:
2024-05-06 @ 7:14 PM
Last Modification Date:
2024-10-26 @ 3:03 PM
Study NCT ID:
NCT05941637
Status:
AVAILABLE
Last Update Posted:
2023-07-12
First Post:
2023-07-03
Brief Title:
An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer Ductal Papillary Chromophobic Oncocytic With Mutations in VHL PBRM1 BAP1 SETD2 VEGF
Sponsor:
Organization:
Lynkcell Europe
Study Design
Study Type:
EXPANDED_ACCESS
Expanded Access Type Individual:
True
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
None
Enrollment Type:
None
Design Primary Purpose:
Design Masking:
Phases:
Observational Models:
Time Perspective List:
Who Masked List: